Postoperative follow-up strategy based on recurrence dynamics for non-small-cell lung cancer

Watanabe, Katsuya; Tsuboi, Masahiro; Sakamaki, Kentaro; Nishii, Teppei; Yamamoto, Taketsugu; Nagashima, Takuya; Ando, Koji; Ishikawa, Yoshihiro; Woo, Tekkan; Adachi, Hiroyuki; Kumakiri, Yutaka; Nakayama, Haruhiko; Masuda, Munetaka

doi:10.1093/ejcts/ezv462

Cited by 43 publications

(34 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…75 LRR after surgery for NSCLC primarily occurs in 2 peaks: the first at 6 to 8 months and the second at 22 to 24 months. 77 An analysis of 74 patients who developed a local recurrence after surgery for stage I NSCLC reported that patients who underwent surgical re-resection survived significantly longer than those who received chemotherapy or radiotherapy, although the 5-year postrecurrence survival rate after repeat surgery remained dismal at only 15%. 78 In a recent study of 40 patients who underwent salvage SBRT for locally recurrent NSCLC that was deemed inoperable, the 18-month OS and local control rates were 77.6% and 87%, respectively.…”

Section: Non-small Cell Lung Cancermentioning

confidence: 99%

Local Cancer Recurrence: The Realities, Challenges, and Opportunities for New Therapies

Mahvi

Liu

Grinstaff

et al. 2018

CA A Cancer J Clinicians

249

167

View full text Add to dashboard Cite

Locoregional recurrence negatively impacts both long-term survival and quality of life for a number of malignancies. For appropriate-risk patients with an isolated, resectable local recurrence, surgery represents the only potentially curative therapy. However, oncologic outcomes remain inferior for patients with locally recurrent disease even after macroscopically complete resection. Unfortunately, these operations are often extensive with significant perioperative morbidity and mortality. This review highlights selected malignancies (mesothelioma, sarcoma, lung cancer, breast cancer, rectal cancer, peritoneal surface malignancies) in which surgical resection is a key treatment modality and where local recurrence plays a significant role in overall oncologic outcome with regards to survival and quality of life. For each type of cancer, the current, state-of-the-art treatment strategies and their outcomes are assessed. The need for additional therapeutic options is presented given the limitations of the current standard therapies. New and emerging treatment modalities, including polymer films and nanoparticles, are highlighted as potential future solutions for both prevention and treatment of locally recurrent cancers. Finally, we identify additional clinical and research opportunities, and propose future research strategies based on the varying patterns of local recurrence among the different cancers.

show abstract

Section: Non-small Cell Lung Cancermentioning

confidence: 99%

Local Cancer Recurrence: The Realities, Challenges, and Opportunities for New Therapies

Mahvi

Liu

Grinstaff

et al. 2018

CA A Cancer J Clinicians

249

167

View full text Add to dashboard Cite

show abstract

“…Eine kürzlich publizierte Studie zeigte innerhalb von diesem Zeitfenster Unterschiede zwischen Männern und Frauen [13]. Eine große Auswertung von über 2 Millionen Krebspatienten im SEER-Register wurde vor kurzem auf dem amerikanischen Krebskongress ASCO vorgestellt.…”

Section: Caveunclassified

Die Nachsorge des Lungenkarzinoms

Tufman

Duell

Schneider³

2020

TumorDiagn u Ther

View full text Add to dashboard Cite

show abstract

“…The median time from surgery to relapse is 13.9 months for local failure and 12.5 months for distant failure [7]. Moreover, Watanabe et al, in an interesting paper [10], note that there are different recurrence peaks during post-operative follow-up. Indeed, a structured multipeak pattern of recurrence risk has been described, with a bimodal recurrence pattern similar to that in patients with breast cancer.…”

Section: Factors and Patterns Of Recurrence Of Non-small Cell Lungmentioning

confidence: 99%

The Role of PET/CT Molecular Imaging in the Diagnosis of Recurrence and Surveillance of Patients Treated for Non-Small Cell Lung Cancer

et al. 2016

View full text Add to dashboard Cite

Non-small cell lung cancer (NSCLC) is the leading cause of cancer mortality worldwide and its prognosis remains poor. Molecular imaging with 18F-FDG PET/CT can metabolically characterize the nature of lesions as benign or malignant, allowing a better staging at the diagnosis of this kind of patient. This advantage can also be applied in the re-staging due to the suspicion of recurrent disease. Many patients have a recurrence of the disease, including surgically treated patients. In the current context, with new personalized oncological treatments, the surveillance for recurrence and its accurate diagnosis are crucial to improve their survival. In this paper, we revise the current knowledge about the clinical and molecular factors related to the recurrent disease. In the context of new, promising, available personalized treatments, the role of molecular imaging with PET/CT and 18F-FDG and non-18F-FDG radiotracers in the follow-up of NSCLC-treated patients is especially attractive and interesting.

show abstract

Postoperative follow-up strategy based on recurrence dynamics for non-small-cell lung cancer

Cited by 43 publications

References 23 publications

Local Cancer Recurrence: The Realities, Challenges, and Opportunities for New Therapies

Local Cancer Recurrence: The Realities, Challenges, and Opportunities for New Therapies

Die Nachsorge des Lungenkarzinoms

The Role of PET/CT Molecular Imaging in the Diagnosis of Recurrence and Surveillance of Patients Treated for Non-Small Cell Lung Cancer

Contact Info

Product

Resources

About